


## Anti-SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody (7D603)

### Product Details

**Ig Type:** IgG1  
**Reactivity:** SARS-CoV-2  
**Molecular Weight:** Theoretical: 140 kDa.  
**Clone:** 7D603  
**Purification:** Protein A purified

### Applications

**Verified Activity:** 1. The ACE2-coated plate is incubated with SARS-CoV-2 Spike RBD-HRP (WT) and Anti-SARS-CoV-2 Spike RBD Neutralizing antibody. Percent inhibition is calculated based on the OD value by inhibiting RBD: ACE2 interaction.  
 2. Direct ELISA was used to detect the binding ability of anti-RBD monoclonal antibody to RBD domain proteins of different SARS-CoV-2 Mutant Strains. Immobilized SARS-CoV-2 RBD proteins, at 2 µg/ml (100ul/Well) can bind Anti-RBD monoclonal antibody-HRP at 1 µg/ml (100ul/Well).



**Application:** ELISA  
**Recommended:** ELISA: 1:5000-10000

### Properties

**Stability & Storage:** Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.  
**Shipping:** Shipping with blue ice.

### Antigen Details

Immunogen: Recombinant Protein: SARS-CoV-2 Spike S1 Protein  
Synonyms: Spike protein S1;Spike glycoprotein;SARS-CoV-2 spike protein;Surface glycoprotein;Spike protein RBD;SPIKE\_SARS2;2019-nCOV Spike protein  
Biology Area: SARS Coronavirus

---

### Research Background

The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481